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REVIEW
about 1%-2% of the entire health care budget in Western coun-
tries.
CHF etiopathogenesis is multifactorial, but coronary syn-
drome (both acute and chronic) still represents the main 
cardiovascular disease leading to heart failure (HF) (1). Heart 
failure’s (HF) pharmacological treatment has gradually been 
developed during the last 3 decades for both acute (i.e. levo-
simendan) and chronic (beta-blockers, ACEis and ARBs) dis-
ease (1).
Recent trials have highlighted the importance of cardiac 
heart rate as a negative prognostic factor in cardiovascular 
diseases (including heart failure) (2-5). Based on this evi-
dence, beta-blockers represent ideal pharmacological agents 
because of their effects on heart rate and myocardial oxygen 
consumption, especially in those patients with chronic isch-
emic heart disease (2, 3).
Low beta-blockers dosages can induce significant clini-
cal improvement in left ventricular systolic function (40% 
reduction in mortality and hospitalization rates, and about 
a 30% increase in left ventricular ejection fraction), also 
providing progressive reduction of cardiac chamber diam-
eters (2-4).
Clinical data from major randomized clinical trials (MDC, 
CIBIS-II, MERIT-HF) suggest that all patients with stable mild 
to moderate systolic heart failure (NYHA class I-III) should take 
advantage of beta-blocker therapy (5). Unfortunately, about 
25% patients with CHF cannot receive beta-blockers, due to dia-
betes, multivessel disease and chronic obstructive pulmonary 
disease (4). Beta-blocker therapy also involves side effects such 
as the development of asthenia and heart rate impairment, 
which limit its widespread administration (4, 5).
The first evidence of heart rate’s prognostic significance 
in cardiovascular disease outcomes was in Levy’s results 
published in 1945 (6). More recent evidence has underlined 
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Introduction
Chronic heart failure (CHF) represents a major cardiovas-
cular morbidity and mortality factor in Western countries. 
Mortality rates are about 50% in people aged over 65, despite 
undeniable advances in pharmacological treatment with the 
introduction of beta-blockers, angiotensin-converting en-
zyme inhibitors (ACEis) and angiotensin receptors blockers 
(ARBs) during the last 2 decades.
The incidence of heart failure (HF) is actually increasing in 
line with the population’s age: from 2.5/1,000 person-years 
for those aged between 55 and 64, to 44/1,000 person-years 
for older patients (over 80). At present, the prevalence of 
heart failure (HF) is approximately 0.4%-2% in people aged 
between 50 and 65 years, up to 10% in people aged over 
75. CHF is much more common among those patients with 
systolic or diastolic dysfunction than in those with normal 
ventricular function. However, even among those with mod-
erate or severe diastolic or systolic dysfunction, less than half 
have recognized CHF (1).
Based on these data, it becomes clear that heart failure (HF) 
is accountable for the majority of incident hospital admissions 
in people aged over 65. Health care costs etc etc for CHF are 
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the close association between heart rate and cardiovascular 
events (especially fatal events such as sudden cardiac death) 
in patients with acute coronary syndrome and heart failure.
Mortality rates increase together with heart rate, espe-
cially for heart rates between 70 and 90 beats per minute 
bpm) (7-10); therefore, a resting heart rate increase repre-
sents an independent cardiovascular mortality factor and is 
accountable for fatal cardiovascular events in patients with 
chronic and stable ischemic cardiopathy (11, 12).
Ivabradine: pharmacological profile and  
clinical application
Ivabradine is an inhibitor of mixed Na+-K+ current that can 
combine with hyperpolarization-activated cyclic nucleotide-
gated (HCN) channels to reduce the transmembrane velocity 
of funny current (If), heart rate and cardiac efficiency. If is a 
mixed Na+-K+ inward current mainly expressed in the sinoatrial 
node, and is a dominant factor for spontaneous depolariza-
tion of cardiac muscle in the diastolic phase (13). HCN chan-
nels are the molecular basis of If. The HCN family includes 4 
members, among which HCN2 and HCN4 are highly expressed 
in cardiac tissues (14). HCN channels were originally described 
in the sinoatrial node, but recent studies have demonstrated 
that If also exists in other cardiac tissues, including atrium and 
ventricle, besides the sinoatrial node, potentially triggering ec-
topic tachyarrhythmia (15). It is well known that the incidence 
of sinoatrial node dysfunction (SND) increases with age and is 
accompanied by atrial fibrillation (AF) and other tachyarrhyth-
mia (16). Decreased functioning of the sinoatrial node facili-
tates electrical remodeling in the atrium and pulmonary veins, 
which can increase the local automaticity and triggered activ-
ity, thus increasing AF risk (17). Aging, as an independent risk 
factor, can also decrease the expression of If and HCN channels 
in the sinoatrial node, increasing their expression in the atrium 
and pulmonary veins (18).
Ivabradine is a selective and specific If inhibitor that can 
affect the spontaneous depolarization of the cells in the 
fourth phase, reducing cellular automaticity (19); therefore, 
as an ion channel inhibitor, ivabradine has potential antiar-
rhythmic effects.
Ivabradine is mainly used for the treatment of several car-
diovascular diseases, including CHF and stable angina pectoris 
in adults with heart rate at rest above 70 bpm, with beta-blocker 
intolerance; alternatively, ivabradine can be added to standard 
beta-blocker therapy in NYHA class II to IV patients with systolic 
dysfunction and heart rate at rest above 75 bpm (20).
Ivabradine treatment seems not to interfere with renal 
function in CHF patients, and all cardiovascular outcomes im-
prove both in patients with impaired renal function and in 
those without renal damage (21).
Based on available data, ivabradine can enable a strong 
reduction of cardiovascular mortality and hospitalization 
rates in CHF patients, together with reduction of mortality 
rates and rehospitalizations for acute heart failure (21).
The European Society of Cardiology (ESC) has suggested 
administration of ivabradine (as stand-alone medication or 
added to standard beta-blocker therapy) in both chronic coro-
nary heart disease patients with heart rate ≥70 bpm and CHF 
patients with heart rate ≥75 bpm (22). Tables I and II show 
standard ivabradine’s dosage and adjustments according to 
heart rate.
Ivabradine and clinical trials
The BEAUTIFUL trial
The Morbidity-Mortality Evaluation of the If Inhibitor Iv-
abradine in Patients With Coronary Disease and Left Ventricular 
TABLE I - Standard ivabradine dosages in management of heart failure patients
Standard dose Hepatic impairment Renal impairment
Initial dose 5 mg twice daily achieving resting 
heart rate of 50-60 bpm
•  Mild or moderate (Child-Pugh A or 
B): no dose adjustment required
•  Severe (Child-Pugh C): therapy 
withdrawal
•  CrCl 15-60 mL/min: No dose  
adjustment required
•  CrCl <15 mL/min: No data are 
available
Maximum dose Not exceeding 7.5 mg twice daily •  Mild or moderate (Child-Pugh A or 
B): no dose adjustment required
•  Severe (Child-Pugh C): therapy 
withdrawal
•  CrCl 15-60 mL/min: No dose  
adjustment required
•  CrCl <15 mL/min: No data are 
available
Data are from (5).
bpm = beats per minute; CrCl = creatinine clearance. 
TABLE II - Ivabradine dose adjustment according to heart rate
Heart rate Dose adjustment
>60 bpm Increase dose by 2.5 mg (given twice 
daily), up to a maximum dose of 
7.5 mg twice daily
50-60 bpm Maintain dose
<50 bpm or signs and 
symptoms of bradycardia
Decrease dose by 2.5 mg (given 
twice daily); if current dose is 2.5 mg 
twice daily, therapy has to be  
discontinued
Data are from (5, 23). 
bpm = beats per minute.
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Dysfunction trial (BEAUTIFUL trial) was the first perspective ran-
domized and controlled double-blind study to evaluate clinical 
correlations between heart rate and cardiovascular events (24).
Inclusion criteria were verified stable chronic coronary dis-
ease in the last 3 months, echocardiography-assessed left ven-
tricular dysfunction, heart rate at rest of ≥60 bpm and presence 
of normal sinus rhythm. The primary end point was a composite 
of cardiovascular mortality, hospitalization for acute myocardial 
infarction and hospitalization for incident or worsening of previ-
ous heart failure. Secondary end points were global mortality, 
cardiovascular-related mortality, hospitalization for heart fail-
ure, acute myocardial infarction or unstable angina and coro-
nary revascularization surgery outcomes.
The aim of the study was to assess efficacy of heart rate 
reduction on the above described cardiovascular end points 
by ivabradine therapy.
The BEAUTIFUL trial’s conclusions were that reduction 
in heart rate with ivabradine does not improve cardiac out-
comes in all patients with stable coronary artery disease and 
left-ventricular systolic dysfunction, but could be used to re-
duce the incidence of coronary artery disease outcomes in 
a subgroup of patients who have heart rates of 70 bpm or 
greater. Therefore a post hoc analysis was proposed that iv-
abradine may reduce major cardiovascular events in patients 
with stable coronary artery disease and left ventricular systol-
ic dysfunction who present with limiting angina. The results 
also suggested that there is no indication for treating patients 
with a heart rate less than 70 bpm with ivabradine if they 
have significant left ventricular dysfunction (ejection fraction 
40%) and do not have symptoms of limiting angina (24).
The SIGNIFY trial
The Study Assessing the Morbidity–Mortality Benefits of 
the If Inhibitor Ivabradine in Patients With Coronary Artery 
Disease Without Heart Failure (SIGNIFY) was a randomized 
controlled double-blind trial in which ivabradine was added 
to standard therapy in 19,102 patients with stable chronic 
coronary artery disease, without heart failure and a heart 
rate ≥70 bpm (25). Patients were assigned to placebo or iv-
abradine (10 mg twice a day to reach a heart rate between 55 
and 60 bpm). Primary end point was cardiovascular death or 
nonfatal myocardial infarction.
After a median 27.8-month follow-up period, the authors 
concluded that addition of ivabradine to standard background 
therapy to reduce heart rate did not improve outcomes among 
patients who had stable coronary artery disease without clini-
cal heart failure.
There are several hypotheses to explain the lack of ben-
efit with ivabradine in the SIGNIFY trial; it is possible that iv-
abradine decreased the heart rate too much, or there may be 
a J-shaped curve for the relationship between heart rate and 
outcome (25).
The SHIFT
The Systolic Heart Failure Treatment With the If inhibitor 
Ivabradine Trial (SHIFT) was a randomized, double-blind, pla-
cebo-controlled, parallel-group study. Patients were eligible 
for enrollment if they had symptomatic heart failure and a 
left ventricular ejection fraction of 35% or lower, were in sinus 
rhythm with a heart rate of 70 bpm or higher, had been admit-
ted to hospital for heart failure within the previous year and 
were on stable background treatment including a beta-blocker 
if tolerated. Patients were randomly assigned to ivabradine ti-
trated to a maximum of 7.5 mg twice daily or matching placebo 
(26). The primary end point was a composite of cardiovascular 
death or hospital admission for worsening heart failure; analy-
sis was by intention to treat. All patients were on background 
therapy with ACEi or ARBs (90%) and/or beta-blockers (90%).
Patients who received ivabradine showed significant pri-
mary (18%) and secondary end point reduction (26%), sup-
porting the importance of heart rate reduction with ivabradine 
for improvement of clinical outcomes in heart failure and con-
firming the important role of heart rate in the pathophysiology 
of this disorder (26).
A subgroup analysis indicated that the effects of ivabradine 
on the primary clinical outcome of SHIFT, and its components, 
were not significantly impacted by beta-blocker dose. Any 
borderline nonsignificant trends were significantly weak-
ened by adjustment for the previously identified interaction 
between baseline heart rate and ivabradine treatment. This 
suggests that any impact of background beta-blocker treat-
ment on the effects of ivabradine are, if anything, marginal 
and that the critical factor driving the benefits of ivabradine 
treatment is heart rate (23).
Ivabradine and chronic kidney disease
Clinical trials on ivabradine use in chronic kidney disease 
are lacking at present time. In 2008, data regarding the role 
of heart rate as a mortality prognostic factor in hemodialysis 
patients were published by Cice et al (27). Four hundred and 
seven normotensive end-stage renal disease (ESRD) patients 
(mean age 56.6 ± 3.3 years) without coronary artery disease 
or left ventricular systolic dysfunction or on antiarrhythmic 
therapy were enrolled. Baseline electrocardiography (ECG) 
at rest, 48-hour ambulatory Holter ECG monitoring and 
standard echocardiography were performed. After a mean 
follow-up of 46 months (range 12-60 months), cardiovascu-
lar and sudden death were considered as primary composite 
end points. Echocardiogram showed a normal left ventricular 
ejection fraction in 91% patients and left ventricular hyper-
trophy in 71%. Mean heart rate by 48-hour Holter ECG was 
81 ± 10.6 bpm. During the follow-up, the all-cause mortality 
rate was 12%, while 9.8% patients died from cardiac causes 
(4.9% by sudden cardiac death). By univariate analysis, age, 
diabetes, left ventricular hypertrophy and increased mean 
heart rate by 48-hour Holter ECG were all significantly relat-
ed to global, cardiovascular and sudden death. Receiver op-
erator characteristic curve analysis identified optimal cutoff 
points for heart rate at >85 bpm and age >65 years associat-
ed with increased cardiovascular risk (p<0.001). The authors 
concluded that in normotensive ESRD patients, increased 
mean heart rate detected by 48-hour Holter ECG is an inde-
pendent determinant of global and cardiovascular mortality. 
Therefore, increased mean heart rate is directly related to 
left ventricular systolic dysfunction, easily assessed by color 
Doppler echocardiography, which provides transmitralic flow 
and left ventricular refilling pressure data. ESRD patients 
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present severe diastolic dysfunction due to left ventricular 
hypertrophy (and consequent myocardial fibrosis), chronic 
ischemic coronary disease, calcium overload and storage 
leading to diastolic filling impairment and myocardial fibers 
abnormally relaxing, together with abnormalities in heart 
rate and rhythm (27).
In 2006, ivabradine was tested (7.5 mg twice daily) in 
hemodialysis patients with higher heart rate at rest, and heart 
failure, both diastolic (54%) and systolic (46%) (28). After 
6 months of therapy, weekly mean heart rate was lower in pa-
tients treated with ivabradine both predialysis and postdialy-
sis. When ivabradine was added to therapy for hemodialysis 
patients with congestive heart failure and preserved ejection 
fraction, it showed positive effects on left ventricular diastolic 
dysfunction, as underlined by decreased left ventricular iso-
volumetric relaxing time (Tab. III).
Ivabradine therapy also led to an improvement of left ven-
tricular systolic function, with an increase of mean ejection 
fraction and shift toward lower NYHA classes, according to 
the SHIFT results (21, 28).
Ivabradine can also be helpful in treating inappropriate 
sinus tachycardia (IST) characterized by unexplained tachy-
cardia (heart rate >100 bpm) and related symptoms at rest. 
IST can be observed in ESRD patients and renal transplant 
recipients. Ivabradine can be used as an alternative to beta-
blockers and calcium channel blockers for management of IST 
when these agents are not tolerated or an overdose is to be 
avoided (29).
Conclusions
The benefit of a decrease in heart rate for patients with 
chronic coronary artery disease and CHF is a reduction in 
cardiovascular mortality rates. Beta-blocker agents have im-
proved patients’ outcomes, but they are often administered 
at unsuitable doses.
Ivabradine, as stand-alone medication or in association 
with beta-blockers, seems to be more effective in improving 
patients’ quality of life in the presence of coronary artery dis-
ease or CHF with heart rates above 70 bpm. In heart failure 
patients, ivabradine decreases cardiovascular mortality and 
heart failure hospitalization rates. The beneficial effects of iv-
abradine therapy become evident in both ischemic and non-
ischemic disease–related heart failure.
In chronic kidney disease patients with glomerular filtra-
tion rates (GFR) above 15 mL/min per 1.73 m2, no dose adjust-
ment seems to be required. At present, no data for patients 
with GFR <15 mL/min per 1.73 m2 are available, although effi-
cacy and safety may be preserved in these patients too; more 
trials are needed, and ivabradine should be used carefully or 
avoided in ESRD patients.
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